WO2015131814A3 - [(芳氧基)(杂芳基)]甲基哌啶衍生物在制备治疗抑郁症的药物中的应用 - Google Patents

[(芳氧基)(杂芳基)]甲基哌啶衍生物在制备治疗抑郁症的药物中的应用 Download PDF

Info

Publication number
WO2015131814A3
WO2015131814A3 PCT/CN2015/073602 CN2015073602W WO2015131814A3 WO 2015131814 A3 WO2015131814 A3 WO 2015131814A3 CN 2015073602 W CN2015073602 W CN 2015073602W WO 2015131814 A3 WO2015131814 A3 WO 2015131814A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicaments
depression
manufacture
treatment
aryloxy
Prior art date
Application number
PCT/CN2015/073602
Other languages
English (en)
French (fr)
Other versions
WO2015131814A2 (zh
Inventor
郭强
赵松
孙家权
刘笔锋
邱印利
李俊红
彭卫娟
Original Assignee
江苏恩华药业股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏恩华药业股份有限公司 filed Critical 江苏恩华药业股份有限公司
Publication of WO2015131814A2 publication Critical patent/WO2015131814A2/zh
Publication of WO2015131814A3 publication Critical patent/WO2015131814A3/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明公开了式I所示的化合物或其药学上可接受的盐在制备治疗抑郁症的药物中的应用。具体涉及式I化合物对5-HT、NE及DA再摄取具有三重抑制作用，其抗抑郁作用比目前临床上使用的单一作用靶点的抗抑郁药（如氟西汀）及双重作用靶点的抗抑郁药（如度洛西汀）可能具有更广的适应症及较小的神经毒副作用。
PCT/CN2015/073602 2014-03-05 2015-03-04 [(芳氧基)(杂芳基)]甲基哌啶衍生物在制备治疗抑郁症的药物中的应用 WO2015131814A2 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410079605.4 2014-03-05
CN201410079605.4A CN104887675B (zh) 2014-03-05 2014-03-05 [(芳氧基)(杂芳基)]甲基哌啶衍生物在制备治疗抑郁症的药物中的应用

Publications (2)

Publication Number Publication Date
WO2015131814A2 WO2015131814A2 (zh) 2015-09-11
WO2015131814A3 true WO2015131814A3 (zh) 2015-10-22

Family

ID=54020920

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/073602 WO2015131814A2 (zh) 2014-03-05 2015-03-04 [(芳氧基)(杂芳基)]甲基哌啶衍生物在制备治疗抑郁症的药物中的应用

Country Status (2)

Country Link
CN (1) CN104887675B (zh)
WO (1) WO2015131814A2 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106349211B (zh) * 2016-08-26 2020-10-16 江苏恩华药业股份有限公司 2-甲基-3-芳氧基-3-杂芳基丙胺类化合物及应用
CN112250676B (zh) * 2020-11-24 2023-05-16 深圳市第二人民医院(深圳市转化医学研究院) 一种具有抗抑郁活性的含氧杂环化合物
CN112279843B (zh) * 2020-11-24 2023-05-16 深圳市第二人民医院(深圳市转化医学研究院) 一种具有抗抑郁活性的含氮杂环化合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2390248A1 (en) * 2010-05-24 2011-11-30 Faes Farma, S.A. Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1854785A1 (en) * 2006-05-12 2007-11-14 Faes Farma, S.A. 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
US20130131079A1 (en) * 2010-05-24 2013-05-23 Faes Farma, S.A. Flufenoxine derivatives for the treatment and prevention of amyloid pathologies
CN103360342B (zh) * 2012-04-09 2015-12-16 江苏恩华药业股份有限公司 3-氰基苯胺烷基芳基哌嗪衍生物及在制备药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2390248A1 (en) * 2010-05-24 2011-11-30 Faes Farma, S.A. Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AURELIO ORJALES ET AL.: "Syntheses and binding studies of new [(aryl) (aryloxy) methyl] piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters", J. MED. CHEM., vol. 46, no. 25, 1 December 2003 (2003-12-01), pages 5512 - 5532, XP002315824 *

Also Published As

Publication number Publication date
CN104887675A (zh) 2015-09-09
WO2015131814A2 (zh) 2015-09-11
CN104887675B (zh) 2018-08-07

Similar Documents

Publication Publication Date Title
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
PH12018500061A1 (en) Oxysterols and methods of use thereof
WO2016064082A3 (ko) 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
WO2014209841A3 (en) Compounds for treating spinal muscular atrophy
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
WO2016011390A8 (en) Irak4 inhibiting agents
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
WO2018042362A9 (en) Muscarinic m1 receptor positive allosteric modulators
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
NZ746825A (en) Oxysterols and methods of use thereof
WO2017053868A8 (en) C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
MX2018003006A (es) Un grupo de compuestos utilizados para el tratamiento o prevencion de hiperuricemia o gota.
PH12016501461A1 (en) 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
WO2014036502A3 (en) Tetracycline compounds
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
MX2019001781A (es) Compuestos de tiofeno condensado utiles como inhibidores de napi-iib.
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
WO2015131814A3 (zh) [(芳氧基)(杂芳基)]甲基哌啶衍生物在制备治疗抑郁症的药物中的应用
WO2015002755A3 (en) Compounds for the treatment of malaria

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15758980

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15758980

Country of ref document: EP

Kind code of ref document: A2